Ethical Review of Emergency Use Protocols in Clinical Trials

Introduction: Ethics Under Pressure During Public Health Emergencies

Public health emergencies such as pandemics, bioterrorism threats, or natural disasters require rapid responses. Clinical trials launched under these conditions are subject to unique ethical scrutiny. The urgency of treatment discovery and deployment must be balanced with the core ethical principles of autonomy, beneficence, non-maleficence, and justice. Emergency Use Protocols (EUPs) push Ethics Committees (ECs) and Institutional Review Boards (IRBs) to act swiftly—sometimes within days—to evaluate risk, consent strategies, and societal benefit.

However, speed must not come at the cost of ethical standards. This article examines the regulatory frameworks, review adaptations, and ethical challenges associated with evaluating emergency-use trials.

1. What Constitutes an Emergency Use Protocol?

An Emergency Use Protocol refers to a clinical trial or therapeutic intervention initiated urgently in response to an unfolding health crisis. These may include:

• Compassionate use of investigational drugs
• Expanded access protocols for seriously ill patients
• Emergency Use Authorization (EUA) studies
• Fast-track vaccine trials during epidemics (e.g., COVID-19, Ebola)

Such trials may bypass traditional design elements (e.g., placebo control, blinding) and operate on compressed timelines, challenging conventional ethical review practices.

2. Regulatory Frameworks for Emergency Approvals

Different regions have codified emergency protocols through fast-track regulatory mechanisms:

• United States: The FDA allows Emergency Use Authorization (EUA) under Section 564 of the FD&C Act.
• European Union: The EMA uses the Conditional Marketing Authorization and Temporary Authorization of Use (TAU) schemes.
• India: The NDCT Rules, 2019 allow waiver of local clinical trials during public health emergencies.
• WHO: Encourages Emergency Use Listing (EUL) and provides ethics guidance for fast-track protocols.

Ethics Committees must interpret these regulations while ensuring ethical review remains robust despite urgency.

3. Expedited Ethical Review: SOPs and Quorum Flexibility

Ethics Committees must adapt their review processes to meet urgent timelines. Key adaptations include:

• Pre-scheduled emergency meetings (virtual or in-person)
• Quorum flexibility (e.g., minimum of three members including one non-scientific)
• Designated subcommittees for rapid assessments
• Rolling reviews based on protocol sections

For example, during the COVID-19 outbreak, many ECs reviewed protocols within 48–72 hours using digital collaboration platforms. This was critical for timely trial initiation without compromising ethical oversight.

4. Challenges in Informed Consent During Emergencies

Securing truly informed consent in emergency settings can be difficult due to:

• Time constraints
• Patient incapacity (e.g., intubated or unconscious)
• Language and literacy barriers
• Restricted physical contact (e.g., isolation wards)

Ethical guidelines like ICH-GCP and FDA regulations allow for consent waivers under strict conditions. Common alternatives include:

• Deferred consent
• Proxy or surrogate consent
• Electronic consent (eConsent) tools

Ethics Committees must evaluate whether the consent process is sufficiently protective while feasible under crisis conditions.

5. Risk-Benefit Evaluation in High Uncertainty

Emergency-use trials often lack full preclinical data or rely on limited observational studies. ECs must navigate heightened risk uncertainty, especially when evidence is evolving daily.

For instance, the early use of hydroxychloroquine in COVID-19 was based on anecdotal evidence, which later proved scientifically inconclusive and potentially harmful. ECs must ask:

• Are the scientific justifications strong enough?
• Are monitoring plans in place to detect harm quickly?
• Are there robust DSMB or interim analyses?

6. Public and Participant Communication Obligations

Emergency trials attract media and public attention. Ethics Committees should ensure:

• Accurate public communication about trial purpose and risks
• Trial registry updates are timely (e.g., via Japanese RCT Portal)
• Participants understand that treatment is investigational

Transparency is essential to maintain public trust and prevent misinformation-driven recruitment or dropout.

7. Data Monitoring and Real-Time Oversight

Given the rapid pace and high stakes, emergency-use protocols demand stringent monitoring, including:

• Real-time SAE/SUSAR reporting
• Frequent DSMB reviews (e.g., every 2 weeks)
• Remote data verification systems
• Adaptations based on accumulating safety signals

In some COVID-19 vaccine trials, interim results led to trial pauses and urgent protocol amendments—a reflection of proactive ethics monitoring.

8. Equity and Fair Access Considerations

Ethical concerns arise around trial access during emergencies. ECs must assess whether:

• Selection criteria are fair and not discriminatory
• Socioeconomically disadvantaged groups have access
• Distribution does not favor certain institutions or geographies unfairly

This is especially important when trial participation is the only way to access a potentially life-saving intervention.

9. Post-Trial Access and Long-Term Ethical Responsibility

What happens after the emergency ends? ECs should require sponsors to outline post-trial access and data use strategies, including:

• Continued access to effective treatments
• Long-term follow-up for safety evaluation
• Data publication commitments and transparency

Many COVID-19 vaccine trials included 24-month follow-up periods and clauses for free post-trial access to the intervention under national immunization plans.

Conclusion: Upholding Ethics Amid Crisis

Ethics in emergency clinical trials is about flexibility without compromise. While urgency demands accelerated processes, the core principles of human dignity, autonomy, and justice must remain intact. Ethics Committees, regulators, and sponsors must collaborate in designing agile yet accountable review mechanisms that protect participants and enable scientific progress under crisis conditions.

With global experience from the COVID-19 pandemic, the path forward lies in embedding emergency SOPs within EC operations, training for crisis ethics, and leveraging digital tools for timely and transparent decisions.

How to Notify and Obtain IRB/IEC Approval for Protocol Amendments

Role of IRBs and IECs in Protocol Amendments

Institutional Review Boards (IRBs) and Independent Ethics Committees (IECs) are responsible for safeguarding the rights and well-being of clinical trial participants. When a sponsor makes changes to a study protocol, it is mandatory to inform the IRB/IEC and seek approval before implementation—unless it’s an urgent safety amendment.

Proper notification to ethics committees ensures compliance with ICH GCP, local laws, and country-specific regulations. Ethics reviews provide an independent opinion on whether the amendment affects participant safety or informed consent.

Which Amendments Require IRB/IEC Review?

• Substantial amendments: Those that impact subject safety, rights, or trial integrity (e.g., dosing changes, inclusion/exclusion criteria)
• Changes to Informed Consent Forms (ICFs)
• Procedural adjustments that introduce new risks or burdens
• Investigator Brochure (IB) updates with new safety findings

Non-substantial changes (e.g., administrative edits) may not require full review but should still be logged and acknowledged by the IRB/IEC.

Step 1: Prepare Your IRB/IEC Submission Package

The ethics committee submission should include:

• Cover letter describing the amendment and rationale
• Tracked and clean copies of the revised protocol
• Summary of changes (clearly formatted)
• Updated ICFs and IB (if applicable)
• IRB application form or cover sheet (as per committee SOP)
• Previous approval letter (for reference)

These documents should be aligned with your organization’s Pharma SOPs and version-controlled.

Step 2: Submit According to IRB/IEC Schedule

Submission timelines depend on the committee type:

• Full Board Review: Amendments reviewed during scheduled IRB meetings (usually monthly)
• Expedited Review: Minimal-risk changes reviewed by a designated IRB member, often within 7–10 days
• Exempt/Administrative Review: For non-substantial changes that require acknowledgment only

Ensure the amendment is submitted well ahead of the scheduled meeting and follow up for confirmation of receipt.

Step 3: IRB/IEC Review Outcomes and Timelines

Once submitted, the IRB/IEC will review the protocol amendment and issue one of the following decisions:

• Approved: No changes required, amendment is accepted as submitted
• Approved with Conditions: Minor edits or clarifications requested before implementation
• Deferred: Major concerns raised—requires resubmission
• Rejected: Amendment is not acceptable due to ethical or safety concerns

Full board reviews typically require 4–6 weeks depending on meeting frequency, while expedited reviews may conclude within 5–10 working days. All outcomes must be documented and filed properly in the Trial Master File (TMF).

Step 4: Documenting in the Trial Master File (TMF)

Regulatory inspectors from the EMA or FDA will assess whether protocol amendments and ethics approvals are filed correctly in the TMF.

• File the submitted documents under TMF Section 01.05.01 (Protocol Amendments)
• Include IRB/IEC approval letters in 02.02.03 or site-specific sections
• Maintain a tracker with submission dates, version numbers, and outcome status
• Link ICF updates to ethics approval letters to ensure version alignment

For TMF templates and tracking tools, visit PharmaValidation.in.

Urgent Amendments: Retrospective IRB/IEC Notification

If a protocol amendment is implemented to eliminate an immediate hazard to subjects, IRB/IEC prior approval is not required. However, notification must be sent within 5 working days. This submission should include:

• A justification memo referencing the safety issue and the change implemented
• The updated protocol (highlighted)
• Communication sent to investigators and participants
• Training logs (if applicable)

IRBs may still issue a retrospective opinion to formally acknowledge the change. Document this thoroughly in the TMF.

Common Mistakes and How to Avoid Them

• Submitting without required documents: Use an IRB-specific checklist to avoid rejections
• Incorrect version numbers: Maintain consistent document versioning across all files
• Missing follow-up: Track timelines and follow up with the IRB to avoid lapses
• Delaying site communication: Share IRB approvals with sites immediately once received

Integrating IRB submission workflows with your CTMS and TMF systems helps eliminate such errors.

Conclusion: Ethics Compliance Strengthens Trial Integrity

Securing timely IRB/IEC review and approval for protocol amendments is not only a regulatory requirement—it reinforces the ethical foundation of every clinical trial. Whether handled by sponsors or CROs, these submissions must be complete, well-documented, and properly tracked.

By standardizing your IRB amendment processes, using compliant cover letters, and maintaining an organized TMF, your team can remain audit-ready and ethically sound at every stage of study execution.